disulfiram has been researched along with Astrocytoma, Grade IV in 29 studies
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate the efficacy and safety of disulfiram and copper as add-on to alkylating chemotherapy in patients with recurrent glioblastoma." | 9.69 | Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial. ( Bartek, J; Carstam, L; Gulati, S; Hylin, S; Jakola, AS; Kinhult, S; Lindskog, M; Löfgren, D; Magelssen, H; Mudaisi, M; Rashid, HB; Salvesen, Ø; Solheim, O; Solheim, TS; Strandéus, M; Werlenius, K, 2023) |
"Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 9.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
"Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models." | 9.27 | Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018) |
"Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM)." | 9.22 | A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. ( Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016) |
"Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed in alcohol use disorder." | 8.02 | Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. ( Eckert, F; Ganser, K; Handgretinger, R; Huber, SM; Klumpp, L; Prause, L; Schleicher, S; Stransky, N; Zips, D; Zirjacks, L, 2021) |
" Development strategies using molecular encapsulation of DS and the parenteral dosage forms improve the anticancer pharmacology of the drug." | 7.01 | Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review. ( Benkő, BM; Lamprou, DA; Sebe, I; Sebestyén, A; Zelkó, R, 2023) |
"Hypoxia is one of the determinants of GSC." | 5.72 | PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo. ( Armesilla, AL; Azar, K; Bian, XW; Kannappan, V; Kilari, RS; Kurusamy, S; Liu, P; Liu, Y; Morris, MR; Najlah, M; Wang, W; Wang, Z, 2022) |
"To evaluate the efficacy and safety of disulfiram and copper as add-on to alkylating chemotherapy in patients with recurrent glioblastoma." | 5.69 | Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial. ( Bartek, J; Carstam, L; Gulati, S; Hylin, S; Jakola, AS; Kinhult, S; Lindskog, M; Löfgren, D; Magelssen, H; Mudaisi, M; Rashid, HB; Salvesen, Ø; Solheim, O; Solheim, TS; Strandéus, M; Werlenius, K, 2023) |
"Disulfiram (DSF) is an anti-alcoholism drug which functions by inhibiting ALDHs." | 5.62 | Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor. ( Gean, PW; Lin, MX; Liu, CC; Sze, CI; Wu, CL, 2021) |
"Disulfiram (DSF) has shown its effectiveness against GBM, especially with copper ion (Cu)." | 5.62 | Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy. ( Iqbal, S; Li, A; Li, C; Ma, D; Ma, L; Ma, W; Qu, Y; Sun, X; Xu, Z; Zhao, Z; Zheng, D, 2021) |
"Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | 5.43 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
"These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients." | 5.38 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012) |
"Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 5.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
"Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models." | 5.27 | Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018) |
"Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM)." | 5.22 | A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. ( Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016) |
"Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed in alcohol use disorder." | 4.02 | Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. ( Eckert, F; Ganser, K; Handgretinger, R; Huber, SM; Klumpp, L; Prause, L; Schleicher, S; Stransky, N; Zips, D; Zirjacks, L, 2021) |
"Constructed from a theoretical framework, the coordinated undermining of survival paths in glioblastoma (GBM) is a combination of nine drugs approved for non-oncological indications (CUSP9; aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, quetiapine, and sertraline) combined with temozolomide (TMZ)." | 3.91 | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. ( Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019) |
" Development strategies using molecular encapsulation of DS and the parenteral dosage forms improve the anticancer pharmacology of the drug." | 3.01 | Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review. ( Benkő, BM; Lamprou, DA; Sebe, I; Sebestyén, A; Zelkó, R, 2023) |
"Among the different types of brain tumors, glioblastoma (GBM) is considered the most aggressive and remains extremely difficult to treat." | 2.52 | Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram. ( Dunn, SE; Rose Pambid, M; Triscott, J, 2015) |
"Hypoxia is one of the determinants of GSC." | 1.72 | PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo. ( Armesilla, AL; Azar, K; Bian, XW; Kannappan, V; Kilari, RS; Kurusamy, S; Liu, P; Liu, Y; Morris, MR; Najlah, M; Wang, W; Wang, Z, 2022) |
"Disulfiram (DSF) is an anti-alcoholism drug which functions by inhibiting ALDHs." | 1.62 | Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor. ( Gean, PW; Lin, MX; Liu, CC; Sze, CI; Wu, CL, 2021) |
"Disulfiram (DSF) has shown its effectiveness against GBM, especially with copper ion (Cu)." | 1.62 | Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy. ( Iqbal, S; Li, A; Li, C; Ma, D; Ma, L; Ma, W; Qu, Y; Sun, X; Xu, Z; Zhao, Z; Zheng, D, 2021) |
"Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | 1.43 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
"These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients." | 1.38 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (3.45) | 29.6817 |
2010's | 22 (75.86) | 24.3611 |
2020's | 6 (20.69) | 2.80 |
Authors | Studies |
---|---|
Fernandes, GFDS | 1 |
Fernandes, BC | 1 |
Valente, V | 1 |
Dos Santos, JL | 1 |
Liu, CC | 1 |
Wu, CL | 1 |
Lin, MX | 1 |
Sze, CI | 1 |
Gean, PW | 1 |
Zirjacks, L | 1 |
Stransky, N | 1 |
Klumpp, L | 1 |
Prause, L | 1 |
Eckert, F | 1 |
Zips, D | 1 |
Schleicher, S | 1 |
Handgretinger, R | 1 |
Huber, SM | 1 |
Ganser, K | 1 |
Kannappan, V | 3 |
Liu, Y | 1 |
Wang, Z | 1 |
Azar, K | 1 |
Kurusamy, S | 1 |
Kilari, RS | 1 |
Armesilla, AL | 3 |
Morris, MR | 1 |
Najlah, M | 1 |
Liu, P | 3 |
Bian, XW | 1 |
Wang, W | 7 |
Benkő, BM | 1 |
Lamprou, DA | 1 |
Sebestyén, A | 1 |
Zelkó, R | 1 |
Sebe, I | 1 |
Werlenius, K | 1 |
Kinhult, S | 1 |
Solheim, TS | 1 |
Magelssen, H | 1 |
Löfgren, D | 1 |
Mudaisi, M | 1 |
Hylin, S | 1 |
Bartek, J | 2 |
Strandéus, M | 1 |
Lindskog, M | 1 |
Rashid, HB | 1 |
Carstam, L | 1 |
Gulati, S | 1 |
Solheim, O | 1 |
Salvesen, Ø | 1 |
Jakola, AS | 1 |
Qu, Y | 1 |
Li, A | 1 |
Ma, L | 1 |
Iqbal, S | 1 |
Sun, X | 1 |
Ma, W | 1 |
Li, C | 1 |
Zheng, D | 1 |
Xu, Z | 1 |
Zhao, Z | 1 |
Ma, D | 1 |
Huang, J | 3 |
Campian, JL | 3 |
Gujar, AD | 2 |
Tsien, C | 1 |
Ansstas, G | 1 |
Tran, DD | 2 |
DeWees, TA | 2 |
Lockhart, AC | 2 |
Kim, AH | 2 |
Mettang, M | 1 |
Meyer-Pannwitt, V | 1 |
Karpel-Massler, G | 4 |
Zhou, S | 2 |
Carragher, NO | 2 |
Föhr, KJ | 1 |
Baumann, B | 2 |
Nonnenmacher, L | 2 |
Enzenmüller, S | 1 |
Dahlhaus, M | 1 |
Siegelin, MD | 1 |
Stroh, S | 1 |
Mertens, D | 1 |
Fischer-Posovszky, P | 1 |
Schneider, EM | 1 |
Halatsch, ME | 5 |
Debatin, KM | 2 |
Westhoff, MA | 2 |
Koh, HK | 1 |
Seo, SY | 1 |
Kim, JH | 1 |
Kim, HJ | 1 |
Chie, EK | 1 |
Kim, SK | 1 |
Kim, IH | 1 |
Chaudhary, R | 1 |
Cohen, AL | 1 |
Fink, K | 1 |
Goldlust, S | 1 |
Boockvar, J | 1 |
Chinnaiyan, P | 1 |
Wan, L | 1 |
Marcus, S | 1 |
Skaga, E | 1 |
Skaga, IØ | 1 |
Grieg, Z | 1 |
Sandberg, CJ | 1 |
Langmoen, IA | 1 |
Vik-Mo, EO | 1 |
Darling, JL | 3 |
Kast, RE | 6 |
Boockvar, JA | 1 |
Brüning, A | 1 |
Cappello, F | 1 |
Chang, WW | 1 |
Cvek, B | 2 |
Dou, QP | 1 |
Duenas-Gonzalez, A | 1 |
Efferth, T | 1 |
Focosi, D | 1 |
Ghaffari, SH | 1 |
Ketola, K | 1 |
Khoshnevisan, A | 1 |
Keizman, D | 1 |
Magné, N | 1 |
Marosi, C | 1 |
McDonald, K | 1 |
Muñoz, M | 1 |
Paranjpe, A | 1 |
Pourgholami, MH | 1 |
Sardi, I | 1 |
Sella, A | 1 |
Srivenugopal, KS | 1 |
Tuccori, M | 1 |
Wirtz, CR | 2 |
Jennewein, C | 1 |
Schneider, M | 1 |
Krause, A | 1 |
Simmet, T | 1 |
Bachem, MG | 1 |
Zembko, I | 1 |
Ahmed, I | 1 |
Farooq, A | 1 |
Dail, J | 1 |
Tawari, P | 2 |
Mcconville, C | 2 |
Triscott, J | 2 |
Rose Pambid, M | 1 |
Dunn, SE | 2 |
Tsien, CI | 1 |
Lun, X | 1 |
Wells, JC | 1 |
Grinshtein, N | 1 |
King, JC | 1 |
Hao, X | 1 |
Dang, NH | 1 |
Wang, X | 1 |
Aman, A | 1 |
Uehling, D | 1 |
Datti, A | 1 |
Wrana, JL | 1 |
Easaw, JC | 1 |
Luchman, A | 1 |
Weiss, S | 1 |
Cairncross, JG | 1 |
Kaplan, DR | 1 |
Robbins, SM | 1 |
Senger, DL | 1 |
Belda-Iniesta, C | 1 |
Brown, S | 2 |
Goktug, T | 1 |
Channathodiyil, P | 2 |
Hugnot, JP | 1 |
Guichet, PO | 1 |
Bian, X | 1 |
Lee, C | 1 |
Hu, K | 1 |
Fotovati, A | 1 |
Berns, R | 1 |
Pambid, M | 1 |
Luk, M | 1 |
Kong, E | 1 |
Toyota, E | 1 |
Yip, S | 1 |
Toyota, B | 1 |
Hothi, P | 1 |
Martins, TJ | 1 |
Chen, L | 1 |
Deleyrolle, L | 1 |
Yoon, JG | 1 |
Reynolds, B | 1 |
Foltz, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma[NCT03034135] | Phase 2 | 23 participants (Actual) | Interventional | 2017-03-09 | Completed | ||
DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial[NCT02678975] | Phase 2/Phase 3 | 88 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months
Intervention | months (Median) |
---|---|
DSF-Cu | 7.1 |
Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months
Intervention | months (Median) |
---|---|
DSF-Cu | 1.7 |
Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months
Intervention | Participants (Count of Participants) |
---|---|
DSF-Cu | 2 |
Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
DSF-Cu | 14 |
ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months
Intervention | Participants (Count of Participants) | |
---|---|---|
Complete response | Partial Response | |
DSF-Cu | 0 | 0 |
Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months
Intervention | percentage of participants (Number) | |
---|---|---|
6 months | 12 months | |
DSF-Cu | 61 | 35 |
5 reviews available for disulfiram and Astrocytoma, Grade IV
Article | Year |
---|---|
Recent advances in the discovery of small molecules targeting glioblastoma.
Topics: Animals; Central Nervous System Neoplasms; Drug Discovery; Glioblastoma; Humans; Neoplastic Stem Cel | 2019 |
Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review.
Topics: Brain; Brain Neoplasms; Disulfiram; Drug Delivery Systems; Glioblastoma; Humans | 2023 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms | 2013 |
Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; Disulfiram; Drug Delivery Systems; Drug Repositi | 2015 |
Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
Topics: Angiotensin-Converting Enzyme Inhibitors; Brain Neoplasms; Captopril; Chemotherapy, Adjuvant; Disulf | 2012 |
4 trials available for disulfiram and Astrocytoma, Grade IV
Article | Year |
---|---|
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Copper; Disulfiram; Female; Glioblastoma; Humans; Ma | 2023 |
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Copper; | 2018 |
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti | 2019 |
A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Disulfiram | 2016 |
20 other studies available for disulfiram and Astrocytoma, Grade IV
Article | Year |
---|---|
Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor.
Topics: Animals; Cell Line, Tumor; Disulfiram; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, | 2021 |
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.
Topics: Disulfiram; Drug Repositioning; Glioblastoma; Temozolomide | 2021 |
PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disulfiram; Glioblastoma; Humans; Hypoxia; Mice; Neoplas | 2022 |
Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy.
Topics: Animals; Brain; Cell Line, Tumor; Copper; Disulfiram; Glioblastoma; Nanomedicine; Rats | 2021 |
Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Anti-Ulcer Agents; Apoptosis; Brain Neoplasms; Carbe | 2018 |
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Brain Neoplasms; Caspase 3; Cell Cycle; Cell Line, Tumor; Dis | 2019 |
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Auranofin; Brain Neoplasms; Cap | 2019 |
How could a drug used to treat alcoholism also be effective against glioblastoma?
Topics: Alcohol Deterrents; Alcoholism; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Disulfi | 2013 |
Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.
Topics: Animals; Cell Line, Tumor; Cell Movement; Disulfiram; Enzyme Inhibitors; Fibronectins; Gene Expressi | 2013 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
Development of disulfiram-loaded poly(lactic-co-glycolic acid) wafers for the localised treatment of glioblastoma multiforme: a comparison of manufacturing techniques.
Topics: Antineoplastic Agents; Brain Neoplasms; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell S | 2015 |
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
Topics: Antineoplastic Agents; Dacarbazine; Disulfiram; Glioblastoma; Humans; Interleukin-18; Ritonavir; Tem | 2015 |
Hot melt extruded and injection moulded disulfiram-loaded PLGA millirods for the treatment of glioblastoma multiforme via stereotactic injection.
Topics: Brain Neoplasms; Cell Line, Tumor; Disulfiram; Drug Carriers; Drug Delivery Systems; Freezing; Gliob | 2015 |
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Copper; Dacarbazine; Disease Mode | 2016 |
Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis.
Topics: Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Cell Differentiation; Cell Division; Chemotherapy, | 2009 |
Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
Topics: Aldehyde Dehydrogenase; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Copper; Cytotoxicity, Immunolo | 2012 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms | 2012 |
High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
Topics: Alcohol Deterrents; Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Disu | 2012 |
Comment on 'cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells'.
Topics: Aldehyde Dehydrogenase; Brain Neoplasms; Copper; Disulfiram; Glioblastoma; Humans; Neoplastic Stem C | 2013 |
Reply: Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
Topics: Aldehyde Dehydrogenase; Brain Neoplasms; Copper; Disulfiram; Glioblastoma; Humans; Neoplastic Stem C | 2013 |